GPhA adds West-Ward exec to board
WASHINGTON — The Generic Pharmaceutical Association recently announced a new addition to its board of directors. The newest member is Michael Raya, CEO of West-Ward Pharmaceuticals, which offers oral solid and injectable generics.
“Michael Raya is a proven industry leader whose addition to our Board will accelerate our work with Congress, the FDA, stakeholders and others to ensure that generic drugs and biosimilars continue providing millions of Americans with safe, effective and more affordable alternatives to costly brand products,” GPhA president and CEO Chip Davis said.
Raya has a Master’s degree from Long Island University and is a graduate of INSEAD’s International Executive program.
“My Board colleagues and the association’s professional staff have been terrific stewards of the industry. I am honored to add my voice to GPhA’s leadership on critical issues of medicine access and affordability,” Raya said.
The full GPhA board is composed of:
Debra Barrett, Teva Americas
Heather Bresch, Mylan N.V. (chair)
Robert Cunard, Aurobindo Pharma US
John Ducker, Fresenius-Kabi
Peter Goldschmidt, Sandoz US
Jim Kedrowski, Sun Pharmaceuticals
Bertrand C. Liang, Pfenex Inc. (chair, GPhA Biosimilars Council)
Marcy Macdonald, Impax Laboratories
Paul McGarty, Lupin Pharmaceuticals
Chirag Patel, Amneal Pharmaceuticals
Tony Pera, Par Pharmaceuticals (secretary/treasurer)
Michael Raya, West-Ward Pharmaceuticals, a Hikma Company
Joseph Renner, Zydus Pharmaceuticals, Inc.
Richard Stec, Perrigo Company
Alok Sonig, Dr. Reddy’s Laboratories
Jeff Watson, Apotex Corporation (vice chair)
Craig Wheeler, Momenta Pharmaceuticals